Bioterrorism threats: Anthrax vaccine contract, botulism antitoxin approval in Canada

Last week, Gaithersburg, MD based biopharmaceutical company, Emergent BioSolutions Inc. announced the signing of a nearly $1 billion contract with the Centers for Disease Control and Prevention (CDC) to supply the Strategic National Stockpile (SNS) approximately 29.4 million doses of BioThrax anthrax vaccine through September 2021. BioThrax is the only anthrax vaccine licensed by the U.S. Food and Drug ["]

The post Bioterrorism threats: Anthrax vaccine contract, botulism antitoxin approval in Canada appeared first on Outbreak News Today.